2
2
1
4
Cat. No. | Product Name | ||
---|---|---|---|
L2170 | 肿瘤免疫治疗小分子化合物库 | 449 compounds | |
449 种靶向肿瘤免疫治疗靶点的小分子,可用于高通量和高内涵筛选,是研究肿瘤免疫治疗的有力工具; |
Cat. No. | Product Name | Target | Signaling Pathways |
---|---|---|---|
T76912 | Atorolimumab | ||
Atorolimumab (P3x22914G4) 是一种单克隆抗体,用于靶向程序性死亡-1 (PD-1) 的免疫疗法。 | |||
T74508 |
SS47
|
Others | Others |
SS47 是一种基于PROTAC 的HPK1降解剂,可发挥蛋白酶体介导的 HPK1 降解。SS47 降解 HPK1 也显着增强了 BCMA CAR-T 细胞研究的体内抗肿瘤功效。HPK1 是一种免疫抑制调节激酶,是肿瘤免疫疗法的有潜力靶点。 |
Cat. No. | Product Name | Target | Signaling Pathways |
---|---|---|---|
T6559 |
Rhamnose monohydrate
L-鼠李糖,L-(+)-Rhamnose Monohydrate |
Others | Others |
Rhamnose monohydrate (L-(+)-Rhamnose Monohydrate) 是一种存在植物和细菌中的单糖。它能通过胞外途径穿过上皮细胞,可以作为肠吸收的标志。Rhamnose monohydrate 免疫原连接物能被用于免疫疗法。 | |||
T5120 |
Rhamnose
6-Deoxyhexopyranose,L-鼠李糖,6-Deoxy-L-mannose,alpha-L-Rhamnose |
Calcium Channel; Endogenous Metabolite | Membrane transporter/Ion channel; Metabolism |
alpha-L-Rhamnose (6-Deoxy-L-mannose) 是存在植物和细菌中的一种单糖。Rhamnose- 免疫原连接物能被用于免疫疗法。Rhamnose 能通过胞外途径穿过上皮细胞,能够作为肠吸收的标志。 |
Cat. No. | Product Name | Species | Expression System |
---|---|---|---|
TMPK-00492 |
IL-18BP Protein (Primary Amine Labeling), Cynomolgus, Recombinant (His), Biotinylated
Igifbp,Interleukin-18-binding protein,IL-18BP |
Cynomolgus | HEK293 Cells |
Cytokines were the first modern immunotherapies to produce durable responses in patients with advanced cancer,components of the interleukin-18 (IL-18) pathway are upregulated on tumour-infiltrating lymphocytes, suggesting that IL-18 therapy could enhance anti-tumour immunity. IL-18BP, a high-affinity IL-18 decoy receptor, is frequently upregulated in diverse human and mouse tumours and limits the anti-tumour activity of IL-18 in mice. IL-18BP Protein (Primary Amine Labeling), Cynomolgus, Recombi... | |||
TMPK-00082 |
IL-18BP Protein, Human, Recombinant (His & Avi), Biotinylated
Igifbp,IL-18BP,IL-18BPA |
Human | HEK293 Cells |
Cytokines were the first modern immunotherapies to produce durable responses in patients with advanced cancer,components of the interleukin-18 (IL-18) pathway are upregulated on tumour-infiltrating lymphocytes, suggesting that IL-18 therapy could enhance anti-tumour immunity. IL-18BP, a high-affinity IL-18 decoy receptor, is frequently upregulated in diverse human and mouse tumours and limits the anti-tumour activity of IL-18 in mice. IL-18BP Protein, Human, Recombinant (His & Avi), Biotinylated... | |||
TMPK-00491 |
IL-18BP Protein, Cynomolgus, Recombinant (His)
Igifbp,Interleukin-18-binding protein,IL-18BP |
Cynomolgus | HEK293 Cells |
Cytokines were the first modern immunotherapies to produce durable responses in patients with advanced cancer,components of the interleukin-18 (IL-18) pathway are upregulated on tumour-infiltrating lymphocytes, suggesting that IL-18 therapy could enhance anti-tumour immunity. IL-18BP, a high-affinity IL-18 decoy receptor, is frequently upregulated in diverse human and mouse tumours and limits the anti-tumour activity of IL-18 in mice. IL-18BP Protein, Cynomolgus, Recombinant (His) is expressed i... | |||
TMPK-00809 |
CD37 Protein, Human, Recombinant (His)
Tspan-26,GP52-40,Tetraspanin-26,MGC120234,CD37 molecule,CD37 |
Human | HEK293 Cells |
CD37 is a tetraspanin expressed prominently on the surface of B cells. It is an attractive molecular target exploited in the immunotherapy of B cell-derived lymphomas and leukemia. Currently, several monoclonal antibodies targeting CD37 as well as chimeric antigen receptor-based immunotherapies are being developed and investigated in clinical trials. Given the unique role of CD37 in the biology of B cells, it seems that CD37 constitutes more than a docking point for monoclonal antibodies, and ta... |